IQVIA Holdings Inc. shares rallied 9.6% post-earnings, primarily driven by a meaningful beat on both revenue and adjusted EPS versus guidance, supported by notable acceleration in organic growth across commercial and clinical segments.

• Total revenue grew 8.4% year over year on a reported basis and 6% at constant currency, beating the high end of guidance.
• Adjusted diluted EPS of $2.90 exceeded the high end of guidance, up 7.4% year over year.
• Organic revenue growth accelerated significantly, with Commercial Solutions doubling and R&D Solutions tripling their respective growth rates year over year.
• Backlog reached a record $34.2 billion, with $8.9 billion expected to convert to revenue within twelve months, reflecting nearly 8% year-over-year growth.
• Strong client demand driven in part by AI integration, with 192 AI agents deployed covering 64 use cases and adoption by 19 of the top 20 pharma companies.